FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

	APPROVAL
CUVID	APPRUVAL

hours per response:

OMB Number: 3235-0287 Estimated average burden

0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	or Section 30(h) of the Investment Company Act of 1940	<u>-</u>					
1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
COOK JOSEPH C JR	CONCERT THE PROPERTY (COM.)	X Director 10% Owner					
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 04/21/2010	Officer (give title Other (specify below) below)					
(Street) MENLO PARK CA 94025	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City) (State) (Zip)							
Table I - Non-Deri	vative Securities Acquired, Disposed of, or Benefic	ially Owned					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock								304,600	D		
Common Stock								1,130,000	<b>I</b> (1)	By Farview Mgmt Co.	
Common Stock	04/21/2010		P		73,427 <sup>(2)</sup>	A	\$1.66	777,411 <sup>(3)</sup>	D		
Common Stock	04/21/2010		P		61,190 <sup>(2)</sup>	A	\$1.66	476,016	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	County			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	(i) (iiisu. 4)	
Stock option (right to buy)	<b>\$</b> 7							(4)	04/17/2012	Common Stock	50,000		50,000	D	
Stock Option (right to buy)	<b>\$</b> 7							(5)	11/23/2013	Common Stock	25,000		25,000	D	
Stock option (right to buy)	\$2.7							(6)	12/19/2017	Common Stock	15,000		15,000	D	
Warrants	\$2.77							03/25/2008	03/24/2015	Common Stock	31,570		119,831 <sup>(7)</sup>	D	
Stock Option (right to buy)	\$2.23							(8)	06/10/2018	Common Stock	15,000		15,000	D	
Warrants	\$2.77							03/25/2008	03/24/2015	Common Stock	14,402		14,402	I	By Farview Mgmt Co.
Warrants	\$2.77							03/25/2008	03/24/2015	Common Stock	25,649		25,649	D	
Stock option (right to buy)	\$0.96							(9)	06/11/2019	Common Stock	30,000		30,000	D	
Warrants	\$1.66	10/16/2009		X			73,427 <sup>(2)</sup>	10/16/2009	10/16/2012	Common Stock	73,427	\$0.125	0	D	
Warrants	\$1.66	10/16/2009		Х			61,190 <sup>(2)</sup>	10/16/2009	10/16/2012	Common Stock	61,190	\$0.125	0	D	
Warrants	\$2.96	04/21/2010		P		73,427 <sup>(10)</sup>		04/21/2010	04/21/2013	Common Stock	73,427	\$0.125	73,427	D	
Warrants	\$2.96	04/21/2010		P		61,190 <sup>(10)</sup>		04/21/2010	04/21/2013	Common Stock	61,190	\$0.125	61,190	D	

#### **Explanation of Responses:**

- 1. These securities are held by Farview Management Co., LLP, of which the reporting person is a general partner.
- 2. Issuance of common stock upon exercise of warrants in accordance with the Securities Purchase Agreement dated as of October 12, 2009.
- $3.\ Does\ not\ include\ 350,\!000\ shares\ of\ which\ Mr.\ Cook\ disclaims\ any\ beneficial\ ownership\ interest.$
- 4. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 4/17/2003 and an additional 1.67% of the total option shares on each monthly anniverary of 4/17/2003 thereafter.
- 5. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 11/23/2004 and an additional 1.67% of the total option shares on each monthly anniverary of 11/23/2004 thereafter.
- 6. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2007 so that the entirety of the option grant will vest within one year.
- 7. Does not include 13,995 warrants of which Mr. Cook disclaims any beneficial ownership interest.
- 8. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 10, 2008 so that the entirety of the option grant will vest within one year.
- 9. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2009 so that the entirety of the option grant will vest on or before the date of Corcept's next Annual Meeting of Stockholders.
- 10. Acquired from the issuer pursuant to a Warrant Purchase Agreement dated April 21, 2010 whereby purchase of the new warrants was conditioned upon the exercise of warrants that had been issued in October 2009 (see also Footnote #2 above).

### Remarks:

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics 04/2 Incorporated attorney-in-fact

04/23/2010

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.